Yuan Jiang

Yuan Jiang

Auto-generated profile, based on publicly available information

Yuan Jiang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2026 in Bioactive Materials
Verified
Journal Article
Open access
QXQing Xu
Qing Xu
YJYuan Jiang
Yuan Jiang
YLYi Luo
Yi Luo
LLLu Li
Lu Li
BJBin Jiang
Bin Jiang
JWJianwei Wang
Jianwei Wang
The current treatment of rheumatoid arthritis (RA) remains limited by severe drug-associated side effects and poor suppression of bone erosion. Herein, we report the development of biomimetic nanoparticles (CEC NPs) that co-deliver celecoxib (CXB) and the lysine-specific demethylase 1 (LSD1) inhibitor CC-90011 via M2 macrophage-derived exosomes (M2 Exos), thereby integrating targeted delivery with innovative multi-mechanistic therapeutic strategies. The M2 Exos enable innate homing to inflamed synovium and osteoclast-rich lesions, while ensuring efficient intracellular delivery. CEC NPs combined repolarize macrophages from the M1 to M2 phenotype, suppress fibroblast-like synoviocyte activation, and critically inhibit bone erosion by blocking the LSD1–NFATc1 signaling pathway in the osteoclast. Collectively, these effects result in potent anti-inflammatory and osteoprotective outcomes. Notably, we identified CC-90011 as a previously unrecognized anti-erosive agent to directly suppress bone erosion in RA treatment. In a collagen-induced arthritis (CIA) model, CEC NPs markedly outperform monotherapies, with pronounced reduction in joint swelling, cartilage degradation, and bone erosion, without systemic toxicity. This work introduces an M2 Exo-based dual-drug delivery system as a versatile strategy for multi-mechanistic modulation of inflammation and bone destruction, offering a promising paradigm that could be extended to other inflammatory and autoimmune bone disorders.